This factor is identical to prokineticin-1 and is a member of the AVIT protein family. Expression of human EG-VEGF messenger RNA is restricted to the steroidogenic glands, ovary, testis, adrenal and placenta and is often complementary to the expression of VEGF. EG-VEGF has been identified as a mitogen specific for the endothelium of steroidogenic glands. EG-VEGF resembles VEGF in that it causes extensive angiogenesis and cyst formation when delivered in the ovary. EG-VEGF differs from VEGF in that it does not promote angiogenesis in the cornea or skeletal muscle. Two receptors have been characterized and are expressed in gastrointestinal organs, endocrine glands and other tissues. The G-protein-coupled receptors ZAQ and I5E both function as the EG-VEGF receptor.
Alternative Names
EGVEGF ; Mambakine ; Prokineticin-1 ; PROK1
Quantity
20 µg
Regulatory
RUO
Source
E. coli
Host
Human
Endotoxin Level
<1.0 EU/μg of recombinant protein as determined by the LAL method.
Biological Activity Comment
Not available.
Weight
10.0 kDa
Description
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Format
Lyophilized PowderRecombinant EG-VEGF was lyophilized from a 0.2 μm filtered PBS solution.
Purity
>95% as determined by SDS-PAGE
Storage
The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.